Objective To explore the diagnosis, treatment, and prognosis of BCR-ABL positive differentiated acute myeloid leukemia (AML). Method: A retrospective analysis was conducted on a case of BCR-ABL positive AML differentiated type (M0) confirmed by cell morphology, immunology, cytogenetics, and molecular biology methods at Southern Hospital of Southern Medical University. The IA "3+7" regimen was combined with dasatinib for induction chemotherapy. The results showed that 0.745% of the patients had cells with unclear classification, and there was no evidence of myeloid differentiation in morphology and cytochemistry. Peroxidase staining positive cells accounted for 0.2%. Immunophenotyping mainly expresses CD34, CD38, CD36, CD13dim, CD33, CD71dim, CD19dim, CD10, HLA-DR differentiation antigens, with almost no expression of cCD22 or cMPO. Fluorescence in situ hybridization showed that 82% of BCR-ABL1 fusion genes were positive, while IGH deletion was positive; Chromosomes 46, XX, t (9; 22) (q34; q11.2) [8]/46, XX [22]; The results of polymerase chain reaction showed that BCR-ABL1 p190 was positive. After IA combined with dasatinib chemotherapy, complete remission was achieved, but due to the combination of central nervous system leukemia, the treatment was ineffective and the patient died. Conclusion The incidence rate of BCR-ABL positive differential AML is low, and there is no unified treatment plan. The traditional AML chemotherapy plan, combined with tyrosine kinase inhibitor, may benefit, but the prognosis is poor.
{"title":"BCR-ABL positive minimally differentiated acute myeloid leukemia: report of one case and review of literature","authors":"Qiang Wang, Q. Wei, Zhongxin Zheng, Zhen Li, Dan Fang, Yong-qiang Wei, R. Feng","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.11.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.11.011","url":null,"abstract":"目的 \u0000探讨BCR-ABL阳性微分化型急性髓系白血病（AML）的诊疗及预后。 \u0000 \u0000 \u0000方法 \u0000回顾性分析南方医科大学南方医院通过细胞形态学、免疫学、细胞遗传学及分子生物学方法确诊的1例BCR-ABL阳性AML微分化型（M0）患者，并予IA\"3+7\"方案联合达沙替尼进行诱导化疗。 \u0000 \u0000 \u0000结果 \u0000患者形态学可见分类不明细胞占0.745，形态学及细胞化学无髓系分化证据，过氧化物酶染色阳性细胞占0.2。免疫分型主要表达CD34、CD38、CD36、CD13dim、CD33、CD71dim、CD19dim、CD10、HLA-DR分化抗原，基本无cCD22、cMPO表达。荧光原位杂交示BCR-ABL1融合基因82%阳性，IGH缺失阳性；染色体示46，XX，t（9；22）（q34；q11.2）[8]/46，XX[22]；聚合酶链反应结果示BCR-ABL1 p190阳性。经IA联合达沙替尼化疗后达到完全缓解，但因合并中枢神经系统白血病，治疗无效死亡。 \u0000 \u0000 \u0000结论 \u0000BCR-ABL阳性微分化型AML发病率低，尚无统一治疗方案，以传统AML化疗方案为主，联合酪氨酸激酶抑制剂可能受益，但预后差。","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"685-688"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46114237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.11.006
R. Pei, Rong-Yan Zhang
Objective To investigate the clinical characteristics and prognosis of adult acute myeloid leukemia (AML) with TLS-ERG fusion gene positive. Methods Adult two AML patients with TLS-ERG fusion gene positive in the First Affiliated Hospital of Zhengzhou University in January 2017 and March 2018, respectively were enrolled, and their clinical characteristics and prognosis were analyzed. Results Both patients with TLS-ERG fusion gene positive were males. According to morphology classification, the first case was classified to AML-M5, and the other one was AML-M4. Both patients' immunophenotypic features showed CD56 expression, and CD25 was expressed in the first patient simultaneously. Both patients were treated with induction and consolidated intensive therapy based on Chinese guidelines for diagnosis and treatment of adult AML (not acute promyelocytic leukemia) and the guidelines for diagnosis and treatment of AML (relapse/refractory) in China. The first patient died 11 months after diagnosis, and the second patient remained in remission until the end of follow-up in February 2019 (12 months after diagnosis). Conclusion TLS-ERG fusion gene has low incidence rate, high recurrence rate, poor reinduction effect, poor prognosis and short survival time in adult AML. Key words: Leukemia, myeloid, acute; Translocation, genetic; TLS-ERG fusion gene
{"title":"Adult acute myeloid leukemia with TLS-ERG fusion gene positive: report of two cases and review of literature","authors":"R. Pei, Rong-Yan Zhang","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.11.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.11.006","url":null,"abstract":"Objective \u0000To investigate the clinical characteristics and prognosis of adult acute myeloid leukemia (AML) with TLS-ERG fusion gene positive. \u0000 \u0000 \u0000Methods \u0000Adult two AML patients with TLS-ERG fusion gene positive in the First Affiliated Hospital of Zhengzhou University in January 2017 and March 2018, respectively were enrolled, and their clinical characteristics and prognosis were analyzed. \u0000 \u0000 \u0000Results \u0000Both patients with TLS-ERG fusion gene positive were males. According to morphology classification, the first case was classified to AML-M5, and the other one was AML-M4. Both patients' immunophenotypic features showed CD56 expression, and CD25 was expressed in the first patient simultaneously. Both patients were treated with induction and consolidated intensive therapy based on Chinese guidelines for diagnosis and treatment of adult AML (not acute promyelocytic leukemia) and the guidelines for diagnosis and treatment of AML (relapse/refractory) in China. The first patient died 11 months after diagnosis, and the second patient remained in remission until the end of follow-up in February 2019 (12 months after diagnosis). \u0000 \u0000 \u0000Conclusion \u0000TLS-ERG fusion gene has low incidence rate, high recurrence rate, poor reinduction effect, poor prognosis and short survival time in adult AML. \u0000 \u0000 \u0000Key words: \u0000Leukemia, myeloid, acute; Translocation, genetic; TLS-ERG fusion gene","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"668-671"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47464993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.11.009
H. Mei
Thrombosis and hemostasis are clinical interdisciplinary subjects involving multiple specialties. Related thrombus and hemorrhagic diseases seriously endanger health. Since the founding of the People's Republic of China, the diagnosis and treatment level of thrombus and hemorrhagic diseases in China have been continuously improved, the theoretical research has been continuously deepened, and a series of fruitful results have been achieved in the basic and clinical research on platelets, coagulation factors, anticoagulant and fibrinolytic systems. This paper summarizes the current situation and future development direction of related representative work. Key words: Thrombosis; Hemorrhagic disorders; Hemostasis
{"title":"Development and current status of research on thrombosis and hemorrhagic diseases in China","authors":"H. Mei","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.11.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.11.009","url":null,"abstract":"Thrombosis and hemostasis are clinical interdisciplinary subjects involving multiple specialties. Related thrombus and hemorrhagic diseases seriously endanger health. Since the founding of the People's Republic of China, the diagnosis and treatment level of thrombus and hemorrhagic diseases in China have been continuously improved, the theoretical research has been continuously deepened, and a series of fruitful results have been achieved in the basic and clinical research on platelets, coagulation factors, anticoagulant and fibrinolytic systems. This paper summarizes the current situation and future development direction of related representative work. \u0000 \u0000 \u0000Key words: \u0000Thrombosis; Hemorrhagic disorders; Hemostasis","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"678-682"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48972730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.11.008
M. Jiang, Shun-dong Ji, K. Dai
Since its inception, anti-platelet antibodies have been an important tool for studying the interaction of platelets with blood components and blood vessels. At the same time, anti-platelet antibodies also play an important role in the detection and diagnosis of hemorrhagic and thrombotic diseases, and become a kind of powerful anti-thrombotic drugs. With the further understanding of the role of platelets in physiological hemostasis and pathological thrombosis, anti-platelet and anti-thrombotic antibodies also seek a balance between better anti-thrombotic effects and less bleeding side effects. Key words: Blood platelets; Antibodies; Thrombosis
{"title":"Development and application of anti-human platelet and anti-thrombotic monoclonal antibodies","authors":"M. Jiang, Shun-dong Ji, K. Dai","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.11.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.11.008","url":null,"abstract":"Since its inception, anti-platelet antibodies have been an important tool for studying the interaction of platelets with blood components and blood vessels. At the same time, anti-platelet antibodies also play an important role in the detection and diagnosis of hemorrhagic and thrombotic diseases, and become a kind of powerful anti-thrombotic drugs. With the further understanding of the role of platelets in physiological hemostasis and pathological thrombosis, anti-platelet and anti-thrombotic antibodies also seek a balance between better anti-thrombotic effects and less bleeding side effects. \u0000 \u0000 \u0000Key words: \u0000Blood platelets; Antibodies; Thrombosis","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"74 1","pages":"676-677"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69842578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.11.004
Y. Miao, Yong-fen Huang, L. Fan, W. Xu, Jian-yong Li, Hao Xu
Objective To study the clinicopathological features and therapeutic regimens of primary testicular lymphoma (PTL). Methods The clinical data of 16 patients diagnosed with PTL from January 2005 to December 2015 in Jiangsu Province Hospital were collected, and the clinicopathological characteristics were retrospectively analyzed. Kaplan-Meier method was used to make the survival analysis. Results The median onset age of 16 patients was 63 years old (33-81 years old). According to Ann Arbor stage, there were 8 cases of stage ⅠE, 2 cases of stage ⅡE, 6 cases of stage Ⅲ-Ⅳ. The initial symptoms included painless solid enlargement of the testis (9 cases), painful testis (3 cases), distending pain of testis (1 case), and the patients had no other systemic symptoms. The pathological type was diffuse large B-cell lymphoma (DLBCL), of which 2 patients were germinal center B-cell (GCB) type and the other 14 patients were non-GCB type. All the patients received the orchiectomy, of which 14 received chemotherapy alone after the operation, 2 received chemotherapy and radiotherapy. Complete follow-up data were available for 14 patients, and the median follow-up time was 23.5 months (1.0-97.0 months). Among 14 patients, complete remission was achieved in 11 patients, partial remission in 1 patient, no response in 1 patient, and 1 patient was undergoing treatment. Among 11 patients with complete remission, 5 patients relapsed, and the recurrence occurred at the central nervous system (3 cases), skin of right lower extremity (1 case), and contralateral testis (1 case). The mean progression-free survival (PFS) time was 19.0 months (14.0-95.0 months). Conclusions Most PTL is primary testis DLBCL, and the comprehensive treatment based on surgery is the main therapy of PTL. Postoperative chemotherapy with or without radiotherapy is recommended to prevent relapse. Key words: Testicular neoplasms; Lymphoma; Orchiectomy; Combined modality therapy
{"title":"Primary testicular lymphoma: a clinical analysis of 16 cases","authors":"Y. Miao, Yong-fen Huang, L. Fan, W. Xu, Jian-yong Li, Hao Xu","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.11.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.11.004","url":null,"abstract":"Objective \u0000To study the clinicopathological features and therapeutic regimens of primary testicular lymphoma (PTL). \u0000 \u0000 \u0000Methods \u0000The clinical data of 16 patients diagnosed with PTL from January 2005 to December 2015 in Jiangsu Province Hospital were collected, and the clinicopathological characteristics were retrospectively analyzed. Kaplan-Meier method was used to make the survival analysis. \u0000 \u0000 \u0000Results \u0000The median onset age of 16 patients was 63 years old (33-81 years old). According to Ann Arbor stage, there were 8 cases of stage ⅠE, 2 cases of stage ⅡE, 6 cases of stage Ⅲ-Ⅳ. The initial symptoms included painless solid enlargement of the testis (9 cases), painful testis (3 cases), distending pain of testis (1 case), and the patients had no other systemic symptoms. The pathological type was diffuse large B-cell lymphoma (DLBCL), of which 2 patients were germinal center B-cell (GCB) type and the other 14 patients were non-GCB type. All the patients received the orchiectomy, of which 14 received chemotherapy alone after the operation, 2 received chemotherapy and radiotherapy. Complete follow-up data were available for 14 patients, and the median follow-up time was 23.5 months (1.0-97.0 months). Among 14 patients, complete remission was achieved in 11 patients, partial remission in 1 patient, no response in 1 patient, and 1 patient was undergoing treatment. Among 11 patients with complete remission, 5 patients relapsed, and the recurrence occurred at the central nervous system (3 cases), skin of right lower extremity (1 case), and contralateral testis (1 case). The mean progression-free survival (PFS) time was 19.0 months (14.0-95.0 months). \u0000 \u0000 \u0000Conclusions \u0000Most PTL is primary testis DLBCL, and the comprehensive treatment based on surgery is the main therapy of PTL. Postoperative chemotherapy with or without radiotherapy is recommended to prevent relapse. \u0000 \u0000 \u0000Key words: \u0000Testicular neoplasms; Lymphoma; Orchiectomy; Combined modality therapy","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"658-662"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41684722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.11.002
F. Gou, Yunhong Huang, Yunfei Hu
Objective To observe the clinical efficacy and prognosis of DA-EPOCH regimen combined with or without rituximab [(R)-DA-EPOCH regimen] in treatment of young newly diagnosed patients with middle and high-risk diffuse large B-cell lymphoma (DLBCL). Methods The clinical data of 107 young newly diagnosed middle to high-risk DLBCL patients treated with (R)-DA-EPOCH regimen at Guizhou Cancer Hospital between November 2014 and December 2018 were retrospectively analyzed. The efficacies were analyzed by grouping according to rituximab (65 cases in R-DA-EPOCH group and 42 cases in DA-EPOCH group), and according to involved-filed radiotherapy (IFRT) after chemotherapy (99 cases with chemotherapy indications including 59 cases with IFRT and 40 cases without IFRT). Results The objective response rate (ORR) was 86.0% (92/107). The 1-, 2-year overall survival (OS) rate was 90.6% and 75.3%. The 1-, 2-year progression-free survival (PFS) rate was 79.1% and 56.5%. The ORR, 1-year OS rate, 2-year OS rate, 1-year PFS rate and 2-year PFS rate in R-DA-EPOCH group were higher than those in DA-EPOCH group [87.7% (57/65) vs. 83.3% (35/42), 94.8% vs. 84.9%, 80.4% vs. 68.2%, 90.5% vs. 77.0%, 61.0% vs. 50.8%, respectively), but there were no statistical differences (all P > 0.05). The ORR of IFRT group and non-IFRT group was 98.2% (56/57) and 80.0% (32/40) (χ 2 = 7.225, P = 0.007). The 2-year OS rate was 86.0% and 63.3% (P < 0.05). Main adverse reactions caused by radiotherapy were local skin mucosa reactions of grade Ⅰ-Ⅱ [42.4% (25/59)]. Multivariate analysis showed that albumin value after treatment was an independent prognosis factor affecting OS rate (95% CI 2.709-21.433, P < 0.01). Gender (95% CI 0.020-0.318, P < 0.01), albumin level (95% CI 2.097-12.219, P < 0.01), Beta 2 microglobulin level (95% CI 0.080-0.602, P < 0.01) and absolute lymphocyte count/absolute monocyte count (95% CI 0.113-0.720, P < 0.01) after treatment were independent prognosis factors affecting PFS rate. Conclusions The young newly diagnosed patients with middle and high-risk DLBCL are highly heterogeneous. Rituximab combined with DA-EPOCH regimen can improve the efficacy of patients. IFRT after chemotherapy may increase the short-term efficacy and OS, and the adverse reactions are tolerant. Key words: Lymphoma, large B-cell, diffuse; Chemotherapy, adjuvant; Molecular targeted therapy; Young adult; Prognosis
{"title":"Clinical study of DA-EPOCH regimen combined with or without rituximab in treatment of young newly diagnosed patients with middle and high-risk diffuse large B-cell lymphoma","authors":"F. Gou, Yunhong Huang, Yunfei Hu","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.11.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.11.002","url":null,"abstract":"Objective \u0000To observe the clinical efficacy and prognosis of DA-EPOCH regimen combined with or without rituximab [(R)-DA-EPOCH regimen] in treatment of young newly diagnosed patients with middle and high-risk diffuse large B-cell lymphoma (DLBCL). \u0000 \u0000 \u0000Methods \u0000The clinical data of 107 young newly diagnosed middle to high-risk DLBCL patients treated with (R)-DA-EPOCH regimen at Guizhou Cancer Hospital between November 2014 and December 2018 were retrospectively analyzed. The efficacies were analyzed by grouping according to rituximab (65 cases in R-DA-EPOCH group and 42 cases in DA-EPOCH group), and according to involved-filed radiotherapy (IFRT) after chemotherapy (99 cases with chemotherapy indications including 59 cases with IFRT and 40 cases without IFRT). \u0000 \u0000 \u0000Results \u0000The objective response rate (ORR) was 86.0% (92/107). The 1-, 2-year overall survival (OS) rate was 90.6% and 75.3%. The 1-, 2-year progression-free survival (PFS) rate was 79.1% and 56.5%. The ORR, 1-year OS rate, 2-year OS rate, 1-year PFS rate and 2-year PFS rate in R-DA-EPOCH group were higher than those in DA-EPOCH group [87.7% (57/65) vs. 83.3% (35/42), 94.8% vs. 84.9%, 80.4% vs. 68.2%, 90.5% vs. 77.0%, 61.0% vs. 50.8%, respectively), but there were no statistical differences (all P > 0.05). The ORR of IFRT group and non-IFRT group was 98.2% (56/57) and 80.0% (32/40) (χ 2 = 7.225, P = 0.007). The 2-year OS rate was 86.0% and 63.3% (P < 0.05). Main adverse reactions caused by radiotherapy were local skin mucosa reactions of grade Ⅰ-Ⅱ [42.4% (25/59)]. Multivariate analysis showed that albumin value after treatment was an independent prognosis factor affecting OS rate (95% CI 2.709-21.433, P < 0.01). Gender (95% CI 0.020-0.318, P < 0.01), albumin level (95% CI 2.097-12.219, P < 0.01), Beta 2 microglobulin level (95% CI 0.080-0.602, P < 0.01) and absolute lymphocyte count/absolute monocyte count (95% CI 0.113-0.720, P < 0.01) after treatment were independent prognosis factors affecting PFS rate. \u0000 \u0000 \u0000Conclusions \u0000The young newly diagnosed patients with middle and high-risk DLBCL are highly heterogeneous. Rituximab combined with DA-EPOCH regimen can improve the efficacy of patients. IFRT after chemotherapy may increase the short-term efficacy and OS, and the adverse reactions are tolerant. \u0000 \u0000 \u0000Key words: \u0000Lymphoma, large B-cell, diffuse; Chemotherapy, adjuvant; Molecular targeted therapy; Young adult; Prognosis","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"647-652"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49019619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective To investigate the clinical characteristics, diagnosis, and treatment of follicular lymphoma (FL) with large abdominal mass and chylothorax. Method: A retrospective analysis was conducted on the laboratory examination, imaging, pathological examination, and treatment of a FL patient with massive abdominal mass and chylothorax admitted to Lanzhou General Hospital of the Lanzhou Military Region, and relevant literature was reviewed. The main clinical manifestation of the patient was recurrent chylothorax, and pelvic magnetic resonance imaging showed a large retroperitoneal mass. Combined with various laboratory tests and neck lymph node biopsy, the diagnosis was confirmed as non Hodgkin's lymphoma, follicular cell type IVB, and regular chemotherapy was given with R-CHOP regimen. Conclusion: The typical clinical manifestation of FL is painless lymph node enlargement, with the appearance of unexplained large abdominal masses and relatively rare chylothorax. Comprehensive examinations such as bone marrow puncture should be performed according to the condition and early stages to avoid misdiagnosis and missed diagnosis.
{"title":"Follicular lymphoma with a large abdominal mass and chylothorax: report of one case and review of literature","authors":"Yonglong Wang, Tao Wu, F. Xue, Ying Han, J. Bai, Cun-bang Wang","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.11.013","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.11.013","url":null,"abstract":"目的 \u0000探讨伴腹部巨大包块及乳糜胸的滤泡性淋巴瘤（FL）的临床特点、诊断及治疗情况。 \u0000 \u0000 \u0000方法 \u0000对兰州军区兰州总医院收治的1例伴腹部巨大包块及乳糜胸的FL患者的相关实验室检查、影像学、病理学检查及治疗情况进行回顾性分析，并复习相关文献。 \u0000 \u0000 \u0000结果 \u0000该患者临床主要表现为反复出现的乳糜胸，盆腔磁共振成像示腹膜后巨大占位，结合各项实验室检查及颈部淋巴结活组织检查明确诊断为非霍奇金淋巴瘤，滤泡细胞型ⅣB期，后给予R-CHOP方案定期化疗。 \u0000 \u0000 \u0000结论 \u0000FL典型的临床表现为无痛性淋巴结肿大，出现原因不明的腹部巨大包块，乳糜胸相对少见，应根据病情及早行骨髓穿刺等综合性检查，避免误诊、漏诊。","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"691-693"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48105680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.11.003
Xiao Lin, Lili Liu, Jianfeng Zhou, Jiangning Zhao
Objective To investigate the clinical value of blood coagulation and fibrinolysis index detection in lymphoma patients. Methods A total of 115 lymphoma patients hospitalized at Zhongshan Hospital of Xiamen University from January 2013 to September 2017 were retrospectively analyzed. According to the diagnostic and therapeutic criteria of lymphoma from World Health Organization (2008), these patients were divided into chemotherapy remission group (76 cases) and chemotherapy non-remission group (39 cases). A total of 138 healthy examination subjects at the same period were selected as the control group. Coagulation factor Ⅶ (FⅦ), D-dimer (D-D), von Willebrand factor antigen (vWF: Ag) and serum lactate dehydrogenase (LDH) levels were measured in all subjects. Kruskal-Wallis test was used to compare the differences of blood coagulation and fibrinolysis indicators in patients with different lymphoma staging and stratified treatment outcomes. Correlation test of D-D and LDH and disease staging was performed by using Spearman correlation analysis. The receiver operating characteristics (ROC) curve was used to analyze the efficacy of D-D in the assisted diagnosis of lymphoma with thrombosis. Results The plasma D-D, vWF: Ag levels and FⅦ activity [the median (interquartile range)] in lymphoma patients were higher than those in healthy controls [1 240 ng/ml (1 610 ng/ml) vs. 250 ng/ml (43 ng/ml), Z = -10.728, P < 0.01; 170 ng/ml (113 ng/ml) vs. 105 ng/ml (28 ng/ml), Z = -6.425, P < 0.01; 120% (26%) vs. 96% (26%), Z = -4.602, P < 0.01]. With the increase of Ann Arbor stage, plasma D-D, vWF: Ag levels and FⅦ activity were also increased gradually (all P < 0.05); plasma D-D, vWF: Ag levels and FⅦ activity in lymphoma with thrombosis group were higher than those in the group without thrombosis (all P < 0.01), D-D and vWF: Ag levels in the chemotherapy remission group were lower than those in the chemotherapy non-remission group (all P < 0.01). Plasma D-D levels were positively correlated with LDH level and Ann Arbor stage (r values were 0.414 and 0.530, respectively, all P < 0.01). When the plasma D-D level was 1 735 ng/ml, the sensitivity of diagnosis of thrombosis in patients with lymphoma was 81.8%, the specificity was 85.7%, the area under the ROC curve was 0.894, and the Youden index was the highest (0.675). Conclusions Clinically, blood coagulation and fibrinolysis in patients with lymphoma can be evaluated by detecting blood coagulation and fibrinolysis indexes such as plasma D-D. Real-time monitoring of plasma D-D level can determine the thrombosis trend of lymphoma patients, and it may play an important role in evaluating the efficacy and prognosis. Key words: Lymphoma; D-dimer; von Willebrand factor antigen; Blood coagulation factor Ⅶ
{"title":"Expressions of plasma D-dimer, von Willebrand factor antigen and blood coagulation factor VII in lymphoma and their clinical significances","authors":"Xiao Lin, Lili Liu, Jianfeng Zhou, Jiangning Zhao","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.11.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.11.003","url":null,"abstract":"Objective \u0000To investigate the clinical value of blood coagulation and fibrinolysis index detection in lymphoma patients. \u0000 \u0000 \u0000Methods \u0000A total of 115 lymphoma patients hospitalized at Zhongshan Hospital of Xiamen University from January 2013 to September 2017 were retrospectively analyzed. According to the diagnostic and therapeutic criteria of lymphoma from World Health Organization (2008), these patients were divided into chemotherapy remission group (76 cases) and chemotherapy non-remission group (39 cases). A total of 138 healthy examination subjects at the same period were selected as the control group. Coagulation factor Ⅶ (FⅦ), D-dimer (D-D), von Willebrand factor antigen (vWF: Ag) and serum lactate dehydrogenase (LDH) levels were measured in all subjects. Kruskal-Wallis test was used to compare the differences of blood coagulation and fibrinolysis indicators in patients with different lymphoma staging and stratified treatment outcomes. Correlation test of D-D and LDH and disease staging was performed by using Spearman correlation analysis. The receiver operating characteristics (ROC) curve was used to analyze the efficacy of D-D in the assisted diagnosis of lymphoma with thrombosis. \u0000 \u0000 \u0000Results \u0000The plasma D-D, vWF: Ag levels and FⅦ activity [the median (interquartile range)] in lymphoma patients were higher than those in healthy controls [1 240 ng/ml (1 610 ng/ml) vs. 250 ng/ml (43 ng/ml), Z = -10.728, P < 0.01; 170 ng/ml (113 ng/ml) vs. 105 ng/ml (28 ng/ml), Z = -6.425, P < 0.01; 120% (26%) vs. 96% (26%), Z = -4.602, P < 0.01]. With the increase of Ann Arbor stage, plasma D-D, vWF: Ag levels and FⅦ activity were also increased gradually (all P < 0.05); plasma D-D, vWF: Ag levels and FⅦ activity in lymphoma with thrombosis group were higher than those in the group without thrombosis (all P < 0.01), D-D and vWF: Ag levels in the chemotherapy remission group were lower than those in the chemotherapy non-remission group (all P < 0.01). Plasma D-D levels were positively correlated with LDH level and Ann Arbor stage (r values were 0.414 and 0.530, respectively, all P < 0.01). When the plasma D-D level was 1 735 ng/ml, the sensitivity of diagnosis of thrombosis in patients with lymphoma was 81.8%, the specificity was 85.7%, the area under the ROC curve was 0.894, and the Youden index was the highest (0.675). \u0000 \u0000 \u0000Conclusions \u0000Clinically, blood coagulation and fibrinolysis in patients with lymphoma can be evaluated by detecting blood coagulation and fibrinolysis indexes such as plasma D-D. Real-time monitoring of plasma D-D level can determine the thrombosis trend of lymphoma patients, and it may play an important role in evaluating the efficacy and prognosis. \u0000 \u0000 \u0000Key words: \u0000Lymphoma; D-dimer; von Willebrand factor antigen; Blood coagulation factor Ⅶ","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"653-657"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45962531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.11.016
Xiuping Wang, Jingyun Shi, Tao Wu, H. Bai
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a kind of highly malignant tumor in the hematological system, which is characterized with low incidence, diverse clinical manifestations, strong invasiveness and poor prognosis, however, currently there has no standard treatment yet. This paper reviews the recent research progress of BPDCN. Key words: Hematologic neoplasms; Blastic plasmacytoid dendritic cell neoplasm; Molecular targeted therapy; Hematopoietic stem cell transplantation; Combined modality therapy
{"title":"Progress of blastic plasmacytoid dendritic cell neoplasms","authors":"Xiuping Wang, Jingyun Shi, Tao Wu, H. Bai","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.11.016","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.11.016","url":null,"abstract":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a kind of highly malignant tumor in the hematological system, which is characterized with low incidence, diverse clinical manifestations, strong invasiveness and poor prognosis, however, currently there has no standard treatment yet. This paper reviews the recent research progress of BPDCN. \u0000 \u0000 \u0000Key words: \u0000Hematologic neoplasms; Blastic plasmacytoid dendritic cell neoplasm; Molecular targeted therapy; Hematopoietic stem cell transplantation; Combined modality therapy","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"698-701"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41872508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.11.017
Caiqin Wang, T. Gao, Xiao-qing Sun
Mantle cell lymphoma (MCL) is an aggressive and rare B-cell lymphoma, accounting for around 6%-8% of non-Hodgkin's lymphoma (NHL). Up to now, there are a lot of studies and reports on the biological behavior, diagnostic criteria and treatments of MCL worldwide. However, due to its high invasiveness, there are still many problems to be solved in terms of prognosis and treatment. This article introduces MCL and its progress in the unsolved clinical problems. Key words: Lymphoma, mantle-cell; Epidemiology; Treatment; Progress
{"title":"Progress of mantle cell lymphoma","authors":"Caiqin Wang, T. Gao, Xiao-qing Sun","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.11.017","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.11.017","url":null,"abstract":"Mantle cell lymphoma (MCL) is an aggressive and rare B-cell lymphoma, accounting for around 6%-8% of non-Hodgkin's lymphoma (NHL). Up to now, there are a lot of studies and reports on the biological behavior, diagnostic criteria and treatments of MCL worldwide. However, due to its high invasiveness, there are still many problems to be solved in terms of prognosis and treatment. This article introduces MCL and its progress in the unsolved clinical problems. \u0000 \u0000 \u0000Key words: \u0000Lymphoma, mantle-cell; Epidemiology; Treatment; Progress","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"701-704"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49500032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：